Govt plans to block $1.3-bn Gland Pharma-Fosun deal

The deal was announced last July when Shanghai Fosun agreed to buy an 86% stake in Gland Pharma

Indian destocking hits GSK consumer health care business
Apart from trade destocking in India, another key reason for a drop reported in consumer health care CER growth in the quarter was divestment of its beverage business in Nigeria
Reuters
Last Updated : Jul 31 2017 | 7:21 PM IST

India's Cabinet Committee on Economic Affairs, chaired by Prime Minister Narendra Modi, has decided to block China's Shanghai Fosun Pharmaceutical Group Co's proposed $1.3 billion takeover of Indian drugmaker Gland Pharma Ltd, Bloomberg reported, citing people familiar with the matter.

Both companies have not been formally notified of the move yet, the report said.

Finance Ministry spokesman D.S. Malik told Reuters that the report was "totally speculative" and that the matter had not yet come before the Cabinet Committee on Economic Affairs (CCEA).

Fosun, Gland Pharma and the CCEA did not immediately respond to requests for comment.

The deal was announced last July when Shanghai Fosun agreed to buy an 86 percent stake in KKR & Co-backed Gland Pharma.

The current stand-off on a plateau next to the mountainous Indian state of Sikkim, which borders China, has ratcheted up tension between the neighbours, who share a 3,500-km (2,175-mile) frontier, large parts of which are disputed.

Gland Pharma, based in Hyderabad, owns four factories from where it supplies a variety of injectables - widely used medicines administered through vials, syringes, bags and pumps, which are harder to make than regular medicines.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 31 2017 | 7:21 PM IST

Next Story